Codexis, Inc. (CDXS) |
| 1.41 0.05 (3.68%) 10-09 16:00 |
| Open: | 1.36 |
| High: | 1.41 |
| Low: | 1.34 |
| Volume: | 553,018 |
| Market Cap: | 152(M) |
| PE Ratio: | -4.15 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 1.75 |
| Resistance 1: | 1.50 |
| Pivot price: | 1.37 |
| Support 1: | 1.36 |
| Support 2: | 1.27 |
| 52w High: | 2.98 |
| 52w Low: | 0.9583 |
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
| EPS | -0.330 |
| Book Value | 0.360 |
| PEG Ratio | 13.53 |
| Gross Profit | 0.172 |
| Profit Margin (%) | -39.55 |
| Operating Margin (%) | -75.29 |
| Return on Assets (ttm) | -11.7 |
| Return on Equity (ttm) | -69.4 |
Mon, 28 Sep 2026
Codexis (NasdaqGS:CDXS) Stock Forecast & Analyst Predictions - Simply Wall Street
Thu, 27 Aug 2026
Codexis Management Will Participate in a Sept. 10 Fireside Chat - Stock Titan
Tue, 11 Aug 2026
Codexis Reports Second Quarter 2026 Financial Results - GlobeNewswire
Tue, 11 Aug 2026
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocatalysis Growth and ECO Synthesis ... - Yahoo Finance
Sun, 26 Jul 2026
Codexis: ECO Synthesis And Runway Reset Warrant An Upgrade (NASDAQ:CDXS) - Seeking Alpha
Sun, 26 Jul 2026
CDXS Stock Falls As Codexis Prices Dilutive Share Offering - Timothy Sykes
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |